Obesity, NASH, RA deals among J&J's latest partnerships

The Johnson & Johnson Innovation unit of Johnson & Johnson (NYSE:JNJ) announced several partnerships, including collaborations concerning obesity, non-alcoholic steatohepatitis and rheumatoid arthritis.

J&J's Janssen Pharmaceuticals Inc. unit partnered with the University of California San Diego School of Medicine to identify mechanisms, pathways, biomarkers, targets and gastric bypass approaches to treat obesity, NASH, chronic kidney disease (CKD) and metabolic liver disease. The multi-project collaboration will use animal and cell models. ...